Advanced in Follicular Lymphoma

Dr. David A. Smith

Hematology Oncology | Hematology | Oncology
210 Se 136th Ave, 
Vancouver, WA 
Advanced in Follicular Lymphoma
210 Se 136th Ave, 
Vancouver, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Smith is a Hematologist Oncology specialist and a Hematologist in Vancouver, Washington. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Pleuropulmonary Blastoma, Follicular Lymphoma, Pancreatoblastoma, and Lung Cancer.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Follicular Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

210 Se 136th Ave, Vancouver, WA 98684

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: August 31, 2022
Intervention Type: Drug
Study Drugs: Docetaxel, Ribociclib, Prednisone, Filgrastim
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Enrollment Status: Terminated
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: August 07, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

5 Total Publications

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: August 17, 2020
Similar Doctors
Distinguished in Follicular Lymphoma
Dr. Andy I. Chen
Hematology | Hematology Oncology | Oncology
Distinguished in Follicular Lymphoma
Dr. Andy I. Chen
Hematology | Hematology Oncology | Oncology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (11.2 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andy Chen is a Hematologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Vitrectomy. Dr. Chen is currently accepting new patients.

Distinguished in Follicular Lymphoma
Dr. Craig Y. Okada
Hematology
Distinguished in Follicular Lymphoma
Dr. Craig Y. Okada
Hematology

University Professional Services

3303 S Bond Ave, 
Portland, OR 
 (10.7 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Okada is a Hematologist in Portland, Oregon. Dr. Okada is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Sezary Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Okada is currently accepting new patients.

Distinguished in Follicular Lymphoma
Dr. Kathryn S. Kolibaba
Hematology Oncology | Hematology | Oncology
Distinguished in Follicular Lymphoma
Dr. Kathryn S. Kolibaba
Hematology Oncology | Hematology | Oncology
210 Se 136th Ave, 
Vancouver, WA 
 (0.1 miles away)
360-944-9889
Languages Spoken:
English

Kathryn Kolibaba is a Hematologist Oncology specialist and a Hematologist in Vancouver, Washington. Dr. Kolibaba is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Chronic B-Cell Leukemia (CBCL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Smith's expertise for a condition
ConditionClose
      View All 32 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile